712 related articles for article (PubMed ID: 37795042)
1. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
4. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
6. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.
Afolabi LO; Afolabi MO; Sani MM; Okunowo WO; Yan D; Chen L; Zhang Y; Wan X
Clin Transl Immunology; 2021; 10(6):e1286. PubMed ID: 34188916
[TBL] [Abstract][Full Text] [Related]
7. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
Chen M; Xu J; Zhou Y; Zhang S; Zhu D
Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
[TBL] [Abstract][Full Text] [Related]
9. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Genome-Editing Technology with CRISPR/Cas9 Variants and Stimuli-Responsive Targeting Approaches within Tumor Cells: A Future Perspective of Cancer Management.
Allemailem KS; Almatroodi SA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Al-Megrin WAI; Aljamaan AN; Rahmani AH; Khan AA
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108214
[TBL] [Abstract][Full Text] [Related]
12. Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.
Afolabi LO; Adeshakin AO; Sani MM; Bi J; Wan X
Immunology; 2019 Oct; 158(2):63-69. PubMed ID: 31315144
[TBL] [Abstract][Full Text] [Related]
13. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
Azangou-Khyavy M; Ghasemi M; Khanali J; Boroomand-Saboor M; Jamalkhah M; Soleimani M; Kiani J
Front Immunol; 2020; 11():2062. PubMed ID: 33117331
[TBL] [Abstract][Full Text] [Related]
15. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
16. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
[TBL] [Abstract][Full Text] [Related]
18. Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics.
Bhat AA; Nisar S; Mukherjee S; Saha N; Yarravarapu N; Lone SN; Masoodi T; Chauhan R; Maacha S; Bagga P; Dhawan P; Akil AA; El-Rifai W; Uddin S; Reddy R; Singh M; Macha MA; Haris M
J Transl Med; 2022 Nov; 20(1):534. PubMed ID: 36401282
[TBL] [Abstract][Full Text] [Related]
19. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
20. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
